Project is identified as a candidate for ceding oversight to a central non U-M IRB. *(multi-site, industry-sponsored, phases III and IV clinical trials)*

Yes

Study team confirms project is a multi-site study being conducted under the oversight of a central IRB listed below where U-M is being added as a performance site.

- Western IRB
- Chesapeake IRB
- Schulman Associates IRB

Yes

Study Team creates a Clinical Trial Routing Form (CTRF) in the electronic proposal management system (eRPM). To ensure proper routing respond in the following manner:

- **Question 1.20.4** - Answer **Yes**
- **Question 1.20.5** - Choose the Central IRB you intend to use. *In the event the IRB of choice isn’t listed, do *not* choose Other - contact the U-M IRB.*
- Study Team completes the Proposal Approval Form (PAF) in the eRPM

Yes

The eResearch ceding application is reviewed by applicable U-M ancillary committees (e.g., PRC, COI, IDS, RDRC/SHUR, CRAO) according to their procedures.

No

Follow standard workflow for studies conducted at U-M.

No

Contact U-M IRB to evaluate the potential for development of a new Central IRB relationship.

No

The eResearch ceding application is reviewed by the U-M IRB for final determination of ceding oversight of the project to a Central IRB. If the application is accepted, an acknowledgement letter ceding oversight is issued for the project.

Upon acknowledgement of ceding application by the U-M IRB and completion of all submission requirements of the Central IRB, the Central IRB is now the IRB of record for this protocol. Study teams remain responsible for ensuring all U-M requirements are maintained.